The abstract is read at the publisher; the summary is JClub's.
CD70 overexpression at diagnosis in uniformly treated follicular lymphoma is linked to inferior progression-free survival, with CD70⁺ tumor cells showing enhanced proliferation and immune activation.
- Why it matters: Even with first-line immunotherapy, some follicular lymphoma patients relapse, so better diagnosis-time biomarkers and targeted strategies are needed to manage high-risk disease.
- What they did: Transcriptomic profiling of diagnosis samples with extended follow-up (>11 years) compared relapsed versus relapse-free cases, then multiplex immunofluorescence validated CD70 overexpression in tumor cells and CD8⁺/CD4⁺ TFH cells.
- The result: Dual CD19-CD70 CAR-T cells (ARI-0001 plus a CD27-based anti-CD70 CAR) showed enhanced cytotoxicity in patient-derived spheroids and superior disease control in follicular lymphoma xenografts, including complete tumor clearance in spleen and bone marrow.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.